Vipadenant

DB06625InvestigationalSmall molecule

Investigated for use/treatment in parkinson's disease.

Chemical structure of Vipadenant
Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in parkinson's disease.Curator reviewed
Formula / weight
C16H15N7O · 321.344 g/mol (avg)
Code names
BIIB-014 · CEB-4520 · V-2006 · VER-11135 · VER-A-00049 · VER-A-00-11 · VER-ADO-49

Resolves to

Compound
UNIILDR3USH1NJCAS442908-10-3ChEMBLCHEMBL447664
Structure
InChIKeyHQSBCDPYXDGTCL-UHFFFAOYSA-NSMILESCC1=CC(CN2N=NC3=C(N=C(N)N=C23)C2=CC=CO2)=CC=C1N
Targets
P29274ADORA2A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Vipadenant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In